Hydrocortison Tiofarma

Hydrocortison Tiofarma is a topical medication that contains the corticosteroid hydrocortisone. It is formulated for cutaneous application and is marketed within the European Union. The product is intended to deliver anti‑inflammatory and immunosuppressive activity directly to the skin. It is supplied without a specified strength, letting clinicians choose appropriate potency.

Hydrocortison Tiofarma is commonly used for the topical management of several inflammatory skin disorders, providing localized relief and is often selected for its favorable safety profile. - Eczema (atopic dermatitis) to relieve itching and inflammation. - Contact dermatitis caused by allergens or irritants. - Psoriasis plaques where reduction of redness and scaling is desired. - Allergic skin reactions such as hives or insect bites. - Minor inflammatory conditions like rash or sunburn. - Seborrheic dermatitis to control flaking and erythema. - Lichen planus lesions where symptomatic relief is required.

Topical hydrocortisone may cause local and, rarely, systemic adverse reactions. The frequency and severity of these effects depend on the duration of use, the treated area, and individual skin sensitivity. Common: - Mild burning, stinging, or itching at the application site. - Slight skin dryness or peeling. - Temporary redness or irritation that resolves after continued use. - Minor folliculitis or acneiform eruptions. - Transient swelling or edema at the site of application. Serious: - Skin atrophy, thinning, or increased fragility with prolonged use. - Development of telangiectasia (visible small blood vessels). - Secondary bacterial, fungal, or viral skin infections. - Hypersensitivity reactions such as contact dermatitis or urticaria. - Systemic absorption leading to adrenal suppression, especially with extensive or prolonged use.

When using Hydrocortison Tiofarma, several precautions should be observed to minimize risks and ensure safe therapy. - Avoid application to broken, infected, or ulcerated skin unless directed by a healthcare professional. - Limit use to the prescribed area and duration; prolonged treatment can increase the chance of skin atrophy. - Do not apply under occlusive dressings unless specifically instructed. - Use caution in patients with diabetes, hypertension, or glaucoma, as systemic absorption may exacerbate these conditions. - Keep the product out of reach of children; accidental ingestion can cause systemic effects. - Discontinue use and seek medical advice if signs of allergic reaction or worsening skin condition occur.

Hydrocortison Tiofarma may interact with other topical or systemic agents that affect skin integrity or glucocorticoid metabolism. Avoid: - Concurrent use of other potent topical corticosteroids on the same area, which can increase the risk of skin atrophy. - Application together with topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus) without medical supervision, as combined immunosuppression may predispose to infection. - Use with systemic glucocorticoids when extensive skin areas are treated, due to additive systemic effects. Use with caution: - Co‑administration of occlusive dressings that enhance drug absorption; monitor for signs of systemic exposure. - Combination with antifungal or antibacterial creams on infected skin; assess for potential irritation. - Use alongside photosensitizing agents; advise patients to limit sun exposure.